Einzeltreffer — DigiBib

Background: Cholestasis is an important predisposing factor for hepatocyte damage, liver fibrosis, primary biliary cirrhosis, and even liver failure. Silybum marianum L. (SM) plant is used in teas or eaten in some countries due to its antioxidant and hepatoprotective properties. Because of its low and poor oral bioavailability, so we improve the therapeutic activity of Silybum marianum L. extract (SM) by studying the potential effects of nanoformulation of Silybum marianium L. extract (nano-SM) on 17α-ethinylestradiol (EE)-induced intrahepatic cholestasis.

Methods: Thirty female Sprague-Dawley rats were divided into 5 groups (6 rats/group). Group I: Rats were received the treatment vehicle and served as normal group. Group II:Rats were injected daily with EE (10 mg/kg) for five successive days. Group III-V: Rats were injected daily with EE (10 mg/kg) and treated with either Ursodeoxycholic acid (UDCA) (40 mg/kg), SM (100 mg/kg) and nano-SM (100 mg/kg) orally once/day throughout the trialfor five successive days, respectively.

Results: Nano-SM greatly dampened the increase in serum levels of total and direct bilirubin, alanine aminotransaminase, aspartate aminotransaminase, and alkaline phosphatase caused by EE. Furthermore, nano-SM increased the hepatic contents of reduced glutathione (GSH) and catalase (CAT) and also upregulated the relative hepatic gene expressions of Rho-kinase (ROCK-1), myosin light chain kinase (MLCK), and myosin phosphatase target subunit (MYPT1) compared to the EE-induced group. Administration of nano-SM reduced hepatic lipid peroxidation and downregulated the relative hepatic expressions of the nuclear factor-kappa B (NF-ҡB) and interleukin-1β (IL-1β). In addition, nano-SM improved the histopathological changes induced by EE.

Conclusion: Nano-SM possessed a superior effect over SM, which can be considered an effective protective modality against EE-induced cholestatic liver injury through its antioxidant, anti-inflammatory activities, and enhancing bile acid (BA) efflux.

Titel:	Mitigation of intrahepatic cholestasis induced by 17α-ethinylestradiol via nanoformulation of Silybum marianum L.
Autor/in / Beteiligte Person:	Salem, MB ; Mohammed, DM ; Hammam, OA ; Elzallat, M
Link:	Full Text Finder (Volltext)
Zeitschrift:	BMC complementary medicine and therapies, Jg. 24 (2024-01-23), Heft 1, S. 51
Veröffentlichung:	London : BioMed Central, [2020]-, 2024
Medientyp:	academicJournal
ISSN:	2662-7671 (electronic)
DOI:	10.1186/s12906-024-04351-2
Schlagwort:	Animals Rats Rats, Sprague-Dawley Silybum marianum Ethinyl Estradiol Antioxidants Plant Extracts Cholestasis, Intrahepatic Asteraceae
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [BMC Complement Med Ther] 2024 Jan 23; Vol. 24 (1), pp. 51. <i>Date of Electronic Publication: </i>2024 Jan 23. MeSH Terms: Cholestasis, Intrahepatic* ; Asteraceae* ; Animals ; Rats ; Rats, Sprague-Dawley ; Silybum marianum ; Ethinyl Estradiol ; Antioxidants ; Plant Extracts References: Plant Foods Hum Nutr. 1999;54(4):285-94. (PMID: 10798339) ; Altern Med Rev. 2011 Sep;16(3):239-49. (PMID: 21951025) ; Int J Mol Sci. 2019 Mar 31;20(7):. (PMID: 30935093) ; J Histochem Cytochem. 1981 Apr;29(4):577-80. (PMID: 6166661) ; Hepatology. 2011 Apr;53(4):1377-87. (PMID: 21480339) ; J Ethnopharmacol. 2009 Jan 21;121(2):185-93. (PMID: 19041708) ; Ind Crops Prod. 2016 May;83:729-737. (PMID: 27182123) ; J Immunol. 1999 Dec 15;163(12):6800-9. (PMID: 10586080) ; Mol Pharmacol. 2015 Jul;88(1):106-12. (PMID: 25943116) ; Phytochem Anal. 2005 Jan-Feb;16(1):7-16. (PMID: 15688950) ; Food Chem Toxicol. 2010 Oct;48(10):2920-4. (PMID: 20667464) ; Biomed Pharmacother. 2016 Jul;81:93-103. (PMID: 27261582) ; Curr Med Chem. 2006;13(9):1055-74. (PMID: 16611084) ; J Biol Chem. 2006 Jun 16;281(24):16625-31. (PMID: 16606610) ; World J Hepatol. 2014 Mar 27;6(3):144-9. (PMID: 24672644) ; Cancer Lett. 2008 Oct 8;269(2):352-62. (PMID: 18472213) ; Front Pharmacol. 2021 Nov 18;12:738504. (PMID: 34867345) ; J Nutr. 1993 Nov;123(11):1939-51. (PMID: 8229312) ; Ter Arkh. 2018 Feb 15;90(2):69-74. (PMID: 30701776) ; Food Chem Toxicol. 2010 Mar;48(3):803-6. (PMID: 20034535) ; Nutr Res. 2017 Apr;40:65-74. (PMID: 28473062) ; Saudi Pharm J. 2010 Jan;18(1):27-33. (PMID: 23960717) ; Naunyn Schmiedebergs Arch Pharmacol. 2021 Mar;394(3):447-455. (PMID: 33034714) ; Biomed Pharmacother. 2017 Nov;95:571-576. (PMID: 28869895) ; PPAR Res. 2013;2013:781348. (PMID: 23997763) ; Turk J Gastroenterol. 2017 Nov;28(6):476-484. (PMID: 29086715) ; BMJ Case Rep. 2020 May 21;13(5):. (PMID: 32444440) ; Heliyon. 2022 Dec 06;8(12):e12027. (PMID: 36531617) ; Phytother Res. 2018 Nov;32(11):2202-2213. (PMID: 30080294) ; Pharmaceuticals (Basel). 2021 May 11;14(5):. (PMID: 34064649) ; Eur J Intern Med. 2018 Jan;47:1-5. (PMID: 28669591) ; Mater Sci Eng C Mater Biol Appl. 2020 Oct;115:111117. (PMID: 32600716) ; Exp Biol Med (Maywood). 2016 Jun;241(11):1250-7. (PMID: 26941058) ; Heliyon. 2023 Aug 28;9(9):e19290. (PMID: 37681189) ; Anal Biochem. 1982 Nov 15;127(1):178-82. (PMID: 7165085) ; PLoS One. 2012;7(2):e31154. (PMID: 22319611) ; Hepatology. 2017 Feb;65(2):722-738. (PMID: 27981592) ; Clin Chim Acta. 2003 Sep;335(1-2):39-47. (PMID: 12927683) ; Molecules. 2017 Jan 24;22(2):. (PMID: 28125040) ; Gut Liver. 2017 Nov 15;11(6):771-780. (PMID: 28292174) ; J Cell Mol Med. 2015 May;19(5):924-33. (PMID: 25683492) ; J Obstet Gynaecol Res. 2016 Mar;42(3):252-7. (PMID: 26786878) ; J Hepatol. 1993 Feb;17(2):241-6. (PMID: 8445238) ; Phytother Res. 2020 Jun;34(6):1291-1309. (PMID: 32026542) ; J Chromatogr Sci. 2015 Feb;53(2):366-72. (PMID: 24895445) ; J Pharm Biomed Anal. 1999 Mar;19(3-4):435-42. (PMID: 10704109) ; J Pharm Sci. 2013 Sep;102(9):3037-57. (PMID: 23653385) ; J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X211068826. (PMID: 35018864) ; Dig Dis. 2015;33(3):357-66. (PMID: 26045270) ; Biomed Pharmacother. 2018 Jun;102:689-698. (PMID: 29604588) ; Molecules. 2019 Jun 07;24(11):. (PMID: 31181687) ; HPB Surg. 2011;2011:306069. (PMID: 21760660) ; Obstet Gynecol. 2014 Jul;124(1):120-133. (PMID: 24901263) ; BMC Gastroenterol. 2013 May 03;13:79. (PMID: 23641818) ; J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 1;902:1-9. (PMID: 22766231) ; J Pharmacol Exp Ther. 1980 Jul;214(1):87-93. (PMID: 7391975) ; Forsch Komplementmed. 2007 Apr;14(2):70-80. (PMID: 17464157) ; Drug Des Devel Ther. 2021 May 04;15:1903-1914. (PMID: 33976540) ; Sci Rep. 2019 Jul 31;9(1):11118. (PMID: 31366891) ; Toxicol Rep. 2022 Mar 08;9:337-345. (PMID: 35284236) ; J Inflamm Res. 2018 Oct 30;11:407-419. (PMID: 30464573) ; Sci Rep. 2016 May 12;6:24709. (PMID: 27169750) ; Cell Prolif. 2009 Apr;42(2):229-40. (PMID: 19317806) ; Semin Liver Dis. 2010 May;30(2):195-204. (PMID: 20422501) Contributed Indexing: Keywords: Bile acid efflux; Ethinylestradiol; Inflammation; Intrahepatic cholestasis; Nanoformulation; Silybum Marianium L. Substance Nomenclature: 423D2T571U (Ethinyl Estradiol) ; 0 (Antioxidants) ; 0 (Plant Extracts) Entry Date(s): Date Created: 20240123 Date Completed: 20240125 Latest Revision: 20240127 Update Code: 20240127 PubMed Central ID: PMC10804614

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Mitigation of intrahepatic cholestasis induced by 17α-ethinylestradiol via nanoformulation of Silybum marianum L.